The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

The Truveta Genome Project aims to establish the world’s largest and most diverse database of genetic information.

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...

Chen was one of 49 Long Island high school seniors named semifinalists Wednesday in the Regeneron contest, the country’s most ...